Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients

Journal of Gastroenterology and Hepatology (Australia)

Volumn 32, Issue 3, 2017, Pages 645-650

  Morio, Kei ^a   Imamura, Michio ^a   Kawakami, Yoshiiku ^a   Morio, Reona ^a   Kobayashi, Tomoki ^a   Yokoyama, Satoe ^a   Nagaoki, Yuko ^a   Kawaoka, Tomokazu ^a   Tsuge, Masataka ^a   Hiramatsu, Akira ^a   Makokha, Grace Naswa ^a   Hayes, C Nelson ^a   Aikata, Hiroshi ^a   Miki, Daiki ^b   Ochi, Hidenori ^b   Honda, Yoji ^c   Mori, Nami ^c   Takaki, Shintaro ^c   Tsuji, Keiji ^c   Chayama, Kazuaki ^a,b  

^a HIROSHIMA UNIVERSITY   (Japan)

^b INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

Author keywords

asunaprevir; chronic hepatitis C; cirrhosis; daclatasvir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; ASUNAPREVIR; DACLATASVIR; NONSTRUCTURAL PROTEIN 5A INHIBITOR; RIBAVIRIN; SIMEPREVIR; ANTIVIRUS AGENT; BMS-790052; IMIDAZOLE DERIVATIVE; ISOQUINOLINE DERIVATIVE; SULFONAMIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; GENOTYPING TECHNIQUE; HEADACHE; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MIDDLE AGED; NEPHROTIC SYNDROME; PHYLOGENY; PRURITUS; RASH; RHINOPHARYNGITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGIC RESPONSE; TREATMENT RESPONSE; YOUNG ADULT; COMBINATION DRUG THERAPY; COMPLICATION; DRUG ADMINISTRATION; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; TREATMENT OUTCOME; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMIDAZOLES; ISOQUINOLINES; LIVER CIRRHOSIS; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015812323     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13511     Document Type: Article

References (22)

1. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671–675.
2. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28: 1687–1695.
3. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958–965.
4. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. N. Engl. J. Med. 2002; 347: 975–982.
5. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver D: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433–1444.
6. Jacobson IM, McHutchison JG, Dusheiko G et al. Telaprevir for previously untreated chronic hepatitis c virus infection. N. Engl. J. Med. 2011; 364: 2405–2416.
7. Bota S, Sporea I, Sirli R et al. Severe adverse events during antiviral therapy in hepatitis C virus cirrhotic patients: a systematic review. World J. Hepatol. 2013; 5: 120–126.
8. Hezode C, Fontaine H, Dorival C et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132–142.
9. Kumada H, Suzuki Y, Ikeda K et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology 2014; 59: 2083–2091.
10. Ikeda K, Saitoh S, Kobayashi M et al. Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data. Hepatol. Res. 2000; 18: 252–266.
11. Fellay J, Thompson A, Ge D et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010; 464: 405–408.
12. Ochi H, Maekawa T, Abe H et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy-a genome-wide study of Japanese HCV virus patients. Gastroenterology 2010; 139: 1190–1197.
13. Yoshimi S, Ochi H, Murakami E et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by Invader assay. PLoS One 2015; 10: e0130022.
14. Prokunina-Olsson L, Muchmore B, Tang W et al. A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. Nat. Genet. 2013; 45: 164–171.
15. Ochi H, Miki D, Hayes CN et al. IFNL4/IL-28B haplotype structure and its impact on susceptibility to hepatitis C virus and treatment response in the Japanese population. J. Gen. Virol. 2014; 95: 1297–1306.
16. Fujino H, Imamura M, Nagaoki Y et al. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C. J. Gastroenterol. 2014; 49: 1548–1556.
17. Nagaoki Y, Imamura M, Kawakami Y et al. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C. Hepatol. Res. 2014; 44: 447–454.
18. Bourliere M, Ouzan D, Rosenheim M et al. Pegylated interferon-a2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003–2007). Antivir. Ther. 2012; 17: 101–110.
19. Hezode C, Fontaine H, Dorival C et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J. Hepatol. 2013; 59: 434–441.
20. Maasoumy B, Port K, Markova AA et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One 2013; 8: e55285.
21. Hezode C, Fontaine H, Dorival C et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132–142.
22. Akuta N, Sezaki H, Suzuki F et al. Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. J. Med. Virol. 2016; 88: 506–511.